Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prucalopride vs Famotidine for Aspiration-associated Symptoms
NCT05455359Phase 4Recruiting
- Sponsor
- Boston Children's Hospital
- Start
- Feb 2025
- Primary completion
- May 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of prucalopride in aspiration pneumonia, esophageal motility disorders (EMD), Gastric motor dysfunction and 1 more (2 arms), sponsored by Boston Children's Hospital. Primary endpoint: Pediatric Cough Quality of Life Questionnaire at 4 weeks. Started Feb 2025; status: recruiting.
02
Drugs
prucalopride
03
Conditions
aspiration pneumoniaesophageal motility disorders (EMD)Gastric motor dysfunctiongastroesophageal reflux disease (GERD)
Beyond the preview
Go deeper on NCT05455359.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05455359.